CSPC Pharma's SYH2051 Combined with Irinotecan Liposome Enters Phase Ib/II Clinical Trial for Advanced Solid Tumors, First Site Launched in China

Stock News
昨天

CSPC PHARMA (01093) has announced that the Phase Ib/II clinical trial of its developed SYH2051 combined with irinotecan liposome for the treatment of advanced solid tumors has officially been initiated at the first research site in China.

The product is a highly selective inhibitor of ataxia-telangiectasia mutated (ATM) protein kinase, registered as a Class 1 chemical drug. It selectively inhibits the activity of ATM kinase, a core component of the cellular DNA damage repair system, thereby preventing DNA damage repair in tumor cells.

The clinical trial now launched is a multicenter, open-label Phase Ib/II study designed to enroll patients with advanced solid tumors, aiming to evaluate the safety and efficacy of the product in combination with irinotecan liposome.

Currently, participant recruitment and screening for this clinical trial are being actively advanced.

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10